Trodelvy is a cancer medicine used to treat adults with a type of breast cancer known as triple-negative breast cancer. It is used when it is not possible to remove cancer with surgery because cancer has spread to areas outside the breast (locally advanced) or to other parts of the body (metastatic ). It is used in patients with two or more prior systemic (whole-body) treatments, including at least one for advanced disease.
The active substance in Trodelvy, sacituzumab govitecan, consists of two active components: a monoclonal antibody (a type of protein) that has been linked to a small molecule, SN-38. The monoclonal antibody has been designed to recognise and attach to Trop-2, a protein on many breast cancer cells. Once attached, the cell takes the medicine, wherein SN-38 becomes active. SN-38 is a cancer medicine that belongs to the group ‘topoisomerase inhibitors’. It blocks an enzyme called topoisomerase I, which is involved in copying cell DNA, needed to make new cells. Cancer cells are prevented from multiplying by blocking the enzyme and eventually dying.
The European Medicines Agency decided that Trodelvy’s benefits are greater than its risks, and it can be authorised for use in the EU.
FDA Approves Trodelvy (Sacituzumab govitecan-hziy) for Triple Negative Breast Cancer.
Download for details: TRODELVY